» Articles » PMID: 14523000

Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Oct 3
PMID 14523000
Citations 172
Authors
Affiliations
Soon will be listed here.
Abstract

Aurora-A, a member of the Aurora/Ipl1-related kinase family, is overexpressed in various types of cancer and considered to play critical roles in tumorigenesis. To better understand the pathological effect of Aurora-A activation, it is first necessary to elucidate the physiological functions of Aurora-A. Here, we have investigated the roles of Aurora-A in mitotic progression with the small interfering RNA, antibody microinjection, and time lapse microscopy using human cells. We demonstrated that suppression of Aurora-A by small interfering RNA caused multiple events to fail in mitosis, such as incorrect separation of centriole pairs, misalignment of chromosomes on the metaphase plate, and incomplete cytokinesis. Antibody microinjection of Aurora-A into late G2 cells induced dose-dependent failure in separation of centriole pairs at prophase, indicating that Aurora-A is essential for proper separation of centriole pairs. When we injected anti-Aurora-A antibodies into prometaphase cells that had separated their centriole pairs, chromosomes were severely misaligned on the metaphase plate, indicating that Aurora-A is required for proper movement of chromosomes on the metaphase plate. Furthermore, inhibition of Aurora-A at metaphase by microinjected antibodies prevented cells from completing cytokinesis, suggesting that Aurora-A also has important functions in late mitosis. These results strongly suggest that Aurora-A is essential for many crucial events during mitosis and that the phosphorylation of a series of substrates by Aurora-A at different stages of mitosis may promote diverse critical events in mitosis to maintain chromosome integrity in human cells.

Citing Articles

Sanguinarine identified as a natural dual inhibitor of AURKA and CDK2 through network pharmacology and bioinformatics approaches.

Li X, You Q Sci Rep. 2024; 14(1):29608.

PMID: 39609491 PMC: 11605095. DOI: 10.1038/s41598-024-81063-0.


Reconstructing the regulatory programs underlying the phenotypic plasticity of neural cancers.

Larsson I, Held F, Popova G, Koc A, Kundu S, Jornsten R Nat Commun. 2024; 15(1):9699.

PMID: 39516198 PMC: 11549355. DOI: 10.1038/s41467-024-53954-3.


The significant others of aurora kinase a in cancer: combination is the key.

Nikhil K, Shah K Biomark Res. 2024; 12(1):109.

PMID: 39334449 PMC: 11438406. DOI: 10.1186/s40364-024-00651-4.


Selective Aurora A-TPX2 Interaction Inhibitors Have Efficacy as Targeted Antimitotic Agents.

Stockwell S, Scott D, Fischer G, Guarino E, Rooney T, Feng T J Med Chem. 2024; 67(17):15521-15536.

PMID: 39190548 PMC: 11403621. DOI: 10.1021/acs.jmedchem.4c01165.


Clinical analysis of 10 cases with subcutaneous panniculitis-like T-cell lymphoma and tissue AURKA expression.

Zheng Z, Teng J, Zeng M, Lu C Skin Res Technol. 2024; 30(8):e13899.

PMID: 39112439 PMC: 11305869. DOI: 10.1111/srt.13899.